Clinical Trials Logo

Clinical Trial Summary

This is a long-term rollover follow-up study for Phase I/II study (Protocol EXG-US-01).


Clinical Trial Description

Patients who received EXG34217 treatment and had at least one follow-up visit (Month 1, 3, 6, or 12) in Study EXG-US-01 will be eligible for this rollover study. Patient will sign a consent form prior to any study related procedure. This study is to add additional follow-up assessments up to 6 years after EXG34217 treatment. This study does not have additional intervention. Additional visits will be every 6 months in the first 3 years and once a year for two years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05868499
Study type Interventional
Source Elixirgen Therapeutics, Inc.
Contact Martine A Francis
Phone 13013438894
Email martine@mafinc.com
Status Not yet recruiting
Phase Phase 1
Start date July 1, 2023
Completion date January 30, 2027